

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations

All items marked with an \* are mandatory to complete.

The maximum number of words for this abstract is 400.

Please be sure to complete the following:

Company name---Cellergy Therapeutics----- \* Website---<https://www.cellergy-bio.com> ---  
----- \*

CEO name---Rachel Diamant-----\* Cell phone number & Email

Select a CATEGORY: Biotech/Pharma

Select one SESSION per abstract from the list below \*

The Future of Aging: Where Longevity Meets Innovation

- **Executive Summary / Investment Rational:**  
Cellergy Therapeutics is pioneering systemic mitochondrial infusion therapy to restore cellular energy and address diseases driven by mitochondrial dysfunction. The company has generated compelling preclinical data, built a scalable GMP-ready manufacturing platform, and established collaborations with Columbia University, Mount Sinai, UC Davis, and Albert Einstein. Cellergy is led by seasoned biotech entrepreneurs with deep company-building, fundraising, and exit experience.
- **Core Technology:**  
Cellergy's proprietary mitochondrial infusion platform enables repeated IV delivery of functional human mitochondria for systemic clinical use. By identifying the optimal mitochondrial source and overcoming the critical quantity gap through scalable, cost-efficient manufacturing, Cellergy generates infusion-ready doses with broad tissue distribution, including brain uptake. The platform supports donor-recipient matching and future AI-based mito-nuclear optimization.
- **Product Profile/Pipeline:**  
Cellergy's pipeline targets diseases associated with mitochondrial dysfunction, including Parkinson's disease, primary mitochondrial disease (PMD), ME/CFS, Long-COVID, and TBI. Preclinical studies demonstrated tissue uptake, favorable safety, and efficacy in Parkinson's and metabolic disease models. The company is advancing programs through collaborations with leading academic centers while preparing for translational and regulatory milestones toward first-in-human studies.
- **Business Strategy:**  
Cellergy will initially focus on high unmet-need indications with accelerated regulatory pathways, including primary mitochondrial diseases and neurodegenerative disorders. The company plans to generate value through strategic partnerships, co-development agreements, licensing opportunities, and clinical milestone achievements. Long term, Cellergy aims to establish mitochondrial infusion therapy as a platform technology applicable across multiple chronic, degenerative, and aging-related diseases.
- **What's Next?**  
Cellergy is advancing IND-enabling studies, GMP manufacturing scale-up, biodistribution and toxicology programs, and expanded efficacy studies across neurological and metabolic indications. Near-term goals include initiating first-in-human clinical studies and strengthening strategic collaborations. Organizationally, the company is expanding translational, regulatory, and clinical capabilities while pursuing additional financing to support clinical development and platform expansion.